ArticlePloS one2025
Comparison of mass spectrometry and fourier transform infrared spectroscopy of plasma samples in identification of patients with fracture-related infections.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesFracture-related infections (FRIs) have significant impact on patient outcomes. Diagnosing FRIs is challenging due to lack of robust, minimally invasive diagnostic tests in the early stages of the disease. The objective of this study was to evaluate the ability of proteomic mass spectrometry (MS) (quantitative approach) and spectral pattern analysis based on fourier transform infrared (FTIR) spectroscopy of plasma samples (qualitative approach) in discriminating between FRI and controls. MATERIALS AND
methodsA prospective case-control study at a level 1 trauma center was conducted. Patients meeting confirmatory FRI criteria were matched with controls without infection based on age, time after surgery, and fracture region. Plasma samples were collected at the time of presentation for FRI and saved for batch analysis. Tandem mass tag liquid chromatography-mass spectrometry was used for proteomics, and FTIR spectroscopy of dried films was used to obtain mid-infrared spectra from samples. Mid-infrared spectra were preprocessed, and for MS data, protein abundance ratios of FRI and controls were compared. Multivariate analysis-based predictive models were developed separately for FTIR-based spectra and MS-based protein ratio data.
resultsThirteen FRI and 13 controls were included in the study. The predictive models based on FTIR spectroscopy data had an average area under the receiver operating characteristic (AUROC) of ≈0.803, CI95(0.8, 0.81), the average sensitivity was ≈ 0. 0.755, CI95(0.75, 0.76), and the specificity was ≈ 0.677, CI95(0.672, 0.682). The MS-based predictive models from protein abundance ratio results had an average AUROC of ≈0.735, CI95(0.732, 0.737), the average sensitivity was ≈ 0.74, CI95 (0.739, 0.747), and the specificity was ≈ 0.653, CI95(0.649, 0.656). DISCUSSION AND
conclusionsMass spectrometry and spectral pattern recognition based on FTIR spectroscopy can both be used to develop predictive models that can discriminate between FRI and control samples. There is potential for both analytical approaches as candidate diagnostic biomarkers in FRI patients that require further validation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.